Search

Displaying results 1441 - 1450 of 4437 in total
  1. Drug

    Tolrestat

    go.drugbank.com/drugs/DB02383
    ApprovedWithdrawn

    It was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death.

  2. Drug

    Sevoflurane

    go.drugbank.com/drugs/DB01236
    ApprovedInvestigationalVet approved

    [A249885] Sevoflurane is three times more potent than [desflurane], but has lower potency compared to [halothane] and [isoflurane]. … [L42340] Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996.

  3. Drug

    Telavancin

    go.drugbank.com/drugs/DB06402
    ApprovedInvestigational

    Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospita...

  4. Drug

    Onasemnogene abeparvovec

    go.drugbank.com/drugs/DB15528
    ApprovedInvestigational

    [Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients. … Developed by AveXis, a Novartis company,[A187253] onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion.

  5. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]

  6. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]

    Products: TAFINLAR HARD CAPSULE 50MG, Rafinlar 50mg Hard Capsule
  7. Drug

    Maftivimab

    go.drugbank.com/drugs/DB15899
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]

  8. Drug

    Beremagene geperpavec

    go.drugbank.com/drugs/DB17831
    ApprovedInvestigational

    Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). … [L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion.

  9. Drug

    Aminoglutethimide

    go.drugbank.com/drugs/DB00357
    ApprovedWithdrawn

    An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens.

  10. Drug

    Acetylcarnitine

    go.drugbank.com/drugs/DB08842
    ApprovedInvestigational

    Acetylcarnitine can be synthesized, but it is also naturally found in adequate amounts in healthy humans.